Tumor-Associated Myeloid Cells in Cancer Immunotherapy

The authors provide an overview of the literature with a focus on the recent research progress evaluating the heterogeneity of tumor-associated myeloid cell (TAMC) origins. They summarize the major therapeutic strategies targeting TAMCs with heterogeneous sources, shedding light on their implications for cancer antitumor immunotherapies.